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Dimethyl fumarate in the management of multiple 
sclerosis: appropriate patient selection and special 
considerations
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Simona Pontecorvo
Department of Neurology and 
Psychiatry, Sapienza University, 
Rome, italy
Abstract: Delayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, 
is the most recently approved oral disease-modifying treatment (DMT) for relapsing multiple 
sclerosis. Two randomized clinical trials (DEFINE and CONFIRM) demonstrated significant 
efficacy in reducing relapse rate and radiological signs of disease activity, as seen on magnetic 
resonance imaging. The DEFINE study also indicated a significant effect of DMF on disabil-
ity worsening, while the low incidence of confirmed disability worsening in the CONFIRM 
trial rendered an insignificant reduction among the DMF-treated groups when compared to 
placebo. DMF also demonstrated a good safety profile and acceptable tolerability, since the 
most common side effects (gastrointestinal events and flushing reactions) are usually transient 
and mild to moderate in severity. Here, we discuss the place in therapy of DMF for individuals 
with relapsing multiple sclerosis, providing a tentative therapeutic algorithm to manage newly 
diagnosed patients and those who do not adequately respond to self-injectable DMTs. Literature 
data supporting the potential role of DMF as a first-line therapy are presented. The possibility of 
using DMF as switching treatment or even as an add-on strategy in patients with breakthrough 
disease despite self-injectable DMTs will also be discussed. Lastly, we argue about the role 
of DMF as an exit strategy from natalizumab-treated patients who are considered at risk for 
developing multifocal progressive leukoencephalopathy.
Keywords: multiple sclerosis, dimethyl fumarate, oral drugs, therapeutic algorithm
Introduction
Multiple sclerosis (MS) is a chronic immunomediated inflammatory disease of the 
central nervous system (CNS) that typically affects young adults.1 The risk of MS is 
greater in women than in men; female:male ratios are between 1.5:1 and 3.5:1 in most 
populations, with a trend toward greater values in the most recent studies.2
The etiology of MS is still not completely known, but presumably involves 
interaction among genetic, environmental, and other factors triggering an aberrant 
autoimmune attack, resulting in damage to myelin and axons.3 The pathogenesis of 
MS involves immune attack against CNS antigens mediated through activated CD4+ 
myelin-reactive T cells, with contribution by B cells.4 Therefore, MS is believed to 
be an autoimmune disorder, but the antigen specificity of the immune response is still 
unknown.4 Pathologically, MS is characterized by perivascular infiltrates of mono-
nuclear cells, demyelination, remyelination, oligodendrocyte depletion, astrocytosis, 
axonal loss, and neuronal degeneration that results in the formation of MS plaques in 
the brain and spinal cord.5
The clinical course of MS may be considered the expression of two clinical phe-
nomena: relapses of acute neurological symptoms, which end with a partial or complete 
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remission, and progression, which refers to the steady and 
irreversible worsening of symptoms.6 This analysis brings 
into the equation the interplay between two biological 
activities: inflammation and degeneration.7
Historically, four clinical MS phenotypes were defined: 
relapsing remitting, secondary progressive, primary progres-
sive, and progressive relapsing.8 However, more recently 
there was a reexamination of MS disease phenotypes that 
included a consideration of inflammatory activity (based 
on the clinical relapse rate and imaging findings), disabil-
ity worsening (as a consequence of relapses), and disease 
progression.9 Accordingly, “progressive relapsing” was 
merged with the primary-progressive phenotype.9
Moreover, the therapy landscape in MS over the last 
few years has dramatically broadened, thus increasing 
the complexity of treatment decisions.10 Therefore, the 
new classification has provided a framework not only for 
communication, prognostication, and clinical trial design 
but also to guide treatment decision-making in daily 
clinical setting.9
Currently available disease-modifying 
treatments for relapsing–remitting 
multiple sclerosis
At the time of writing, 12 disease-modifying treatments 
(DMTs) are available for the treatment of relapsing MS 
(R-MS; Table 1): self-injectable drugs, including four IFNβ 
formulations and two glatiramer acetate (GA) formulations; 
an immunosuppressive agent (mitoxantrone); two humanized 
monoclonal antibodies (natalizumab and alemtuzumab); 
and three oral compounds (fingolimod, teriflunomide, and 
dimethyl fumarate [DMF]).11–29
Historically, self-injectable DMTs have been the main-
stay of MS therapy, and are still widely used in patients 
with R-MS. Based on data from the head-to-head random-
ized controlled trials (RCTs) INCOMIN and EVIDENCE, 
both high-dose and highly frequently administered IFNβ 
formulations are considered more efficacious than low-dose 
subcutaneous (SC) IFNβ
1a
, especially in the short term.30,31 
However, a Danish RCT and some postmarketing studies 
did not fully support this observation, providing conflicting 
results.32–37 According to findings from three head-to-head 
RCTs (BECOME, REGARD, and BEYOND), the efficacy 
of GA is comparable to that of IFNβ
1a
 and IFNβ
1b
,38–40 even 
though IFNβ appeared better than GA in controlling radio-
logical disease activity, as seen on brain magnetic resonance 
imaging (MRI).41,42 By contrast, the CombiRx study found 
GA significantly better than IFNβ in reducing the risk of 
relapse; however, this RCT was not specifically designed to 
compare IFNβ and GA.43 More recently, a large multicenter 
real-world study showed slightly lower relapse incidence 
among patients treated with GA or SC IFNβ
1a
 relative to 
intramuscular IFNβ
1a
 and SC IFNβ
1b
, without any difference 
in terms of disability worsening.44
Despite their excellent safety profile, IFNβ and GA 
may be poorly tolerated, due to systemic or injection-
related adverse events, leading to discontinuation or lack of 
adherence in a relevant number of patients.45,46 Moreover, 
self-injectable DMTs are only partially effective in prevent-
ing clinical and MRI activity.47 Mitoxantrone was approved 
Table 1 Currently available disease-modifying treatments for relapsing multiple sclerosis
Molecule Route Dosage Schedule Brand 
name
Company
iFNβ1b SC 250 μg eOD Betaseron
Betaferon
extavia
Bayer
Bayer
Novartis
iFNβ1a iM
SC
30 μg
22/44 μg
Ow
Tiw
Avonex
Rebif
Biogen
Merck Serono
PeGylated iFNβ1a SC 125 μg e2w Plegridy Biogen
Glatiramer acetate SC
SC
20 mg
40 mg
OD
Tiw
Copaxone
Copaxone 40
Teva
Teva
Mitoxantrone iv 8–12 mg/mq e1-3M Novantrone wyeth
Natalizumab iv 300 mg e4w Tysabri Biogen
Alemtuzumab iv 12 mg O5D (1st year)
O3D (2nd year)
Lemtrada Genzyme
Fingolimod PO 0.5 mg OD Gilenya Novartis
Teriflunomide PO 14 mg OD Aubagio Genzyme
Dimethyl fumarate PO 240 mg BiD Tecfidera Biogen
Abbreviations: BiD, bis in die (twice daily); e1-3M, every 1–3 months; e2w, every 2 weeks; eOD, every other day; iM, intramuscular; iv, intravenous; O3D, over 3 days; 
OD, once daily; Ow, once weekly; PO, per os (by mouth); SC, subcutaneous; Tiw, ter in week (thrice weekly).
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for rapidly worsening R-MS or secondary-progressive MS, 
and has proven its efficacy in several trials;18,19,48 however, the 
increased incidence of cardiotoxicity and treatment-related 
leukemia has discouraged its more widespread use.49,50 
According to European Medicines Agency criteria, mono-
clonal antibodies, such as natalizumab and alemtuzumab, 
are currently used in adult patients with R-MS who do not 
adequately respond to a self-injectable DMT or in those pre-
senting rapidly evolving disease activity, defined by clinical 
or imaging features.51,52
There is evidence that alemtuzumab is superior to SC 
IFNβ
1a
 in reducing relapse rate, disability worsening, and 
MRI activity.21–23 Moreover, nonrandomized postmarketing 
observational studies support the use of natalizumab rather 
than self-injectable DMTs or fingolimod in nonresponders 
to a first-line treatment course.53–55 Despite the two drugs’ 
impressive efficacy in controlling disease activity, and even 
in reducing disability (in some cases), there are several safety 
concerns, due to the increased risk of opportunistic infections 
and autoimmunomediated conditions in patients treated with 
natalizumab and alemtuzumab.56,57
Orally administered DMTs (fingolimod, teriflunomide, 
and DMF) represent a significant therapeutic advance, since 
the oral administration route represents an attractive oppor-
tunity for patients and may potentially promote enhanced 
therapeutic adherence.58 Moreover, data from RCTs has 
shown that these oral drugs are at least equivalent or even 
superior to self-injectable DMTs in terms of efficacy.25,29,59 
Fingolimod demonstrated higher efficacy than intramuscular 
IFNβ
1a
 on both clinical and MRI end points; however, there 
were no between-group differences in terms of disability 
outcomes.25 Although CONFIRM was not designed as a head-
to-head RCT, its post-hoc analysis showed a significantly 
greater treatment effect of DMF versus GA in reducing 
relapse rate and MRI activity, but not disability worsening.29 
A similar risk of treatment failure (defined as first occurrence 
of confirmed relapse or permanent treatment discontinuation 
for any cause) was reported between teriflunomide 14 mg 
and SC IFNβ
1a
 44 μg in the TENERE study.59 However, 
despite these encouraging data, even oral DMTs may have 
safety and tolerability issues, especially when compared 
with the good and well-known long-term safety profile of 
self-injectable platform therapies.60 Table 2 shows the main 
findings in terms of efficacy, safety, and tolerability regarding 
oral DMTs currently used in R-MS.
Dimethyl fumarate for relapsing–
remitting multiple sclerosis: 
mechanisms of action
Fumaric acid (FA) and its derivatives have been used for 
decades as topical and oral long-term treatments for psoriasis, 
a long-lasting inflammatory skin disease. In 1994, Germany 
approved an oral compound of FA esters (FAEs) containing 
DMF and ethyl hydrogen fumarate as mixed salts for pso-
riasis treatment, but it is also used off-license in many other 
countries.61 Evidence shows that FAEs provided long-term 
safety and effectiveness in patients with psoriasis.62,63 Based 
on prolonged experience, and combined with the positive 
results obtained in the animal model of MS,64 the prospect 
of utilizing DMF for autoimmune conditions other than 
psoriasis was envisioned.65
In 2003, Biogen purchased licensing rights to develop 
a second-generation DMF for treating psoriasis and MS,66 
two conditions sharing an autoimmune T-cell-mediated 
pathogenetic pathway.67 DMF is a lipophilic ester of FA 
(a key intermediate in the citric acid cycle used by cells 
Table 2 Main features of the currently approved oral disease-modifying treatments for relapsing multiple sclerosis (only data relative 
to currently approved dose presented)
Molecule
Trials
Efficacy Safety Tolerability
Relapsea Disabilitya
Fingolimod
FReeDOMS24
TRANSFORMS25
-55%
-51.5%b
-26.6%b
-25.3%c
Herpes virus and other opportunistic 
infections,d bradyarrhythmias, macular 
edema, skin neoplasms
High burden for first-dose administration
Teriflunomide
TeMSO26
TOweR27
-31.5%
-36.3%
-29.8%
-31.5%
Liver-enzyme increase, neutropenia, 
pregnancy issues
Hair thinning, gastrointestinal events
Dimethyl fumarate
DeFiNe28
CONFiRM29
-41.3%
-44.0%
-38%
-21%c
Leukopenia, lymphopeniae Flushing, gastrointestinal events
Notes: aRelative reduction in relapse rate (primary end point) and disability worsening (secondary end point) versus placebo; bversus iFNβ1a 30 μg once weekly (12-month 
follow-up); cnot significant; dincluding progressive multifocal encephalopathy and cryptococcosis; efour patients older than 50 years developed progressive multifocal 
encephalopathy following a prolonged grade 2 or 3 lymphopenia.
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to produce energy) that after oral assumption is rapidly 
metabolized into its active metabolite monomethyl fumarate 
(MMF) by intestinal esterases.68,69 The currently used oral 
delayed-release DMF formulation allows the compound 
to bypass the stomach and be released at intestinal level. 
After administration, the blood concentration of MMF 
peaks at approximately 2–2.5 hours (T
max
), but it is delayed 
with coingestion of a fat-rich meal. This latter phenomenon 
underpins the observed lower incidence of metabolism-
related side effects of DMF when the drug is taken with 
high-calorie food.70,71
Preclinical studies have demonstrated that DMF has 
immunomodulating and antioxidant properties, and simi-
larly to other DMTs, such as IFNβ, GA, and fingolimod, 
DMF exerts a pleiotropic effect.72 The immunomodulating 
properties of DMF mainly encompass the induction of a 
shift from a proinflammatory Th1- to an anti-inflammatory 
Th2-cytokine pattern.73 Due to its lipophilic nature, the DMF 
derivative MMF is able to translocate into blood cells, where 
it interacts with glutathione and promotes its depletion.74,75 
The rapid decrease of intracellular glutathione leads to a 
rebound increase in concentration that in turn suppresses 
the translocation of nuclear NFκB into the nucleus, thereby 
preventing the transcription of inflammatory cytokines and 
adhesion molecules.75
The antioxidant potential of DMF appears to be mediated 
by two different molecular pathways involving the nuclear 
factor Nrf276 and the high-affinity receptor for nicotinic acid/
niacin and β-hydroxybutyrate HCAR2.77,78 Under normal 
conditions, Nrf2 is sequestered in the cytosol via Keap1; 
DMF/MMF irreversibly bind to Keap1, leading to transloca-
tion of Nrf2 into the nucleus, thus imitating the physiological 
oxidative stress-response pathway that activates cell-defense 
mechanisms.76,79
HCAR2 is a G-protein-coupled membrane receptor; its 
activation results in reduced cAMP levels, which in turn 
leads to neutrophil apoptosis. After crossing the blood–
brain barrier (BBB), MMF binds to HCAR2 and switches 
microglia and astrocytes to an anti-inflammatory phenotype, 
thereby indirectly affecting neuronal survival and function, 
including restoration of synaptic alterations occurring in 
experimental MD models.77,78 The potential for a direct 
effect on CNS-resident cells is supported by the evidence 
that upon oral administration, DMF is rapidly metabolized 
to MMF, which crosses the BBB and achieves detectable 
levels in the CNS.79
This latter pathway is also implicated in the flushing 
reaction, a well-recognized side effect of DMF due to 
increased prostaglandin levels; indeed, by binding HCAR2, 
MMF induces prostanoid-forming enzymes in different 
epidermal cell types.80 Although the proposed mechanism of 
action does not include effects on lymphocytes, DMF shifts 
the immunophenotypes of circulating T cells, leading to a 
reduction of memory cells and a relative expansion of naïve 
cells, regardless of the absolute lymphocyte count (ALC).81 
In addition, ALC reduction of about a third has been observed 
in RCTs and in a recent post-marketing experience,28,29 with 
the most relevant reduction for CD8 and CD19 cells (40% 
and 48%, respectively).82,83
Dimethyl fumarate for relapsing 
multiple sclerosis: efficacy data
In 2006, an 18-week open-label prospective study in 
ten patients with R-MS demonstrated that 720 mg FAEs 
(240 mg thrice weekly) induced significant reduction in 
number and volume of contrast-enhancing lesions (CELs) 
compared with baseline (P,0.05); this effect was sustained 
over a further 48-week treatment phase with 360 mg 
FAEs (120 mg thrice weekly) and even after a 4-week 
washout period.84
A 48-week, Phase IIB, randomized, placebo-controlled, 
double-blind study of DMF was subsequently conducted on 
257 patients with R-MS.85 When compared with placebo, 
patients treated with DMF 240 mg TID (ter in die [thrice 
daily]) had a 69% reduction in the mean cumulative 
number of CELs (P=0.002), 48% reduction in the mean 
number of new or newly enlarging T
2
-hyperintense lesions 
(P,0.001), and 53% reduction in the mean number of new 
T
1
-hypointense lesions (P=0.01). The annualized relapse rate 
(ARR) also decreased by 32% in the active group versus 
placebo (P,0.05). Subsequent data analysis also showed 
that the percentage of CELs evolving to T
1
-hypointense 
lesions (“black holes”) was 34% lower with DMF treatment 
versus placebo.86
Following these seminal studies, two pivotal Phase III 
randomized double-blind clinical trials were conducted 
in patients with R-MS and at least one relapse in the pre-
vious year or at least one CEL within 6 weeks prior to 
randomization: DEFINE and CONFIRM.28,29
In the 2-year DEFINE study, the AAR decreased by 
53% and 48% in the DMF 240 mg BID (bis in die [twice 
daily]) and 240 mg TID groups, respectively, when compared 
with placebo (P,0.001). The risk of confirmed disability 
worsening was also reduced by 38% and 34% in the DMF 
240 mg BID and 240 mg TID groups, respectively, when 
compared with placebo (P#0.01). Moreover, both DMF 
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doses significantly reduced the numbers of CELs and new or 
enlarging T
2
-hyperintense lesions (P,0.001).28 A potential 
cytoprotective and remyelinating effect of DMF was also sug-
gested by a subset analysis of the DEFINE study in patients 
who underwent unconventional MRI investigation based on 
magnetization-transfer ratio.87
The 2-year CONFIRM trial, which included an active-
comparator group of patients treated with GA, demonstrated 
ARR reductions of 44%, 51%, and 29% in the DMF 240 mg 
BID, DMF 240 mg TID, and GA groups, respectively, com-
pared to the placebo group (P#0.01).29 Reductions in disabil-
ity worsening versus placebo were not significant in the DMF 
groups or the GA group, probably due to the low proportion 
of patients with disability worsening in the placebo group. 
Compared with placebo, DMF 240 mg BID, DMF 240 mg 
TID, and GA significantly reduced the numbers of CELs, new 
or enlarging T
2
-hyperintense lesions, and new T
1
-weighted 
hypointense lesions (P,0.001). Although CONFIRM was 
not specifically designed as a head-to-head study, a post hoc 
direct evaluation showed a stronger effect of both DMF 240 
mg BID and DMF 240 mg TID in reducing the number of 
new or enlarging T
2
-hyperintense lesions when compared to 
GA (P,0.01). Moreover, DMF 240 mg TID but not DMF 
240 mg BID was superior to GA in reducing ARR and new 
T
1
-hypointense lesions (P,0.05). No significant differences 
were found in proportion of relapsing patients with, or time 
to, disability worsening.29 A more recent post hoc analysis 
showed that DMF significantly reduced the risk of inflam-
matory disease activity (defined as such an event as relapse, 
CELs, or new/enlarging T
2
-hyperintense lesions) over 2 
years compared with GA; the differential treatment effect 
was seen by 24 weeks.88
A subsequent MRI analysis of CONFIRM also showed 
that DMF BID and TID produced significant and consistent 
reductions versus placebo of lesion volumes, but reductions 
in brain atrophy and magnetization-transfer ratio changes 
did not reach statistical significance.89
An integrated analysis of the two pivotal Phase III 
trials showed that at 2 years, DMF 240 mg BID and TID 
significantly reduced the ARR and the risks of relapses, 
with 12-week and 24-week confirmed disability worsen-
ing in respect to placebo.90 Although the efficacy of DMF 
is generally consistent across patient subgroups, the most 
relevant effect of DMF is observed in younger treatment-
naïve individuals with low Expanded Disability Status Scale 
(EDSS) score. Moreover, patients treated with both DMF 
doses improved in some patient-reported outcomes referring 
to quality of life with respect to placebo.91
ENDORSE (NCT00835770) is an ongoing 8-year 
extension phase including patients enrolled in both pivotal 
trials to evaluate the long-term efficacy and safety of DMF.92 
An interim analysis of this extension study supports the use 
of DMF as a long-term treatment option for patients with 
R-MS, since early treatment with DMF was associated with 
lower relapse rates and reduced risk of disability worsening 
over 5 years when compared with patient groups originally 
randomized to GA or placebo.93
According to a recent Cochrane review, there is moderate-
quality evidence to support the use of DMF for reducing both 
the proportion of relapsing patients and the ARR, while there 
is no evidence to support the benefit on disability outcome, 
and the quality of available data is too low to evaluate the 
benefit on MRI outcomes.94
Dimethyl fumarate for relapsing 
multiple sclerosis: safety and 
tolerability data
Overall, the short-term safety profile for DMF in patients with 
R-MS is highly favorable,28,29 and long-term safety analysis 
from ENDORSE study sustains a good benefit:risk ratio for 
this oral compound.95
The commonest adverse events observed in patients 
receiving DMF include flushing, gastrointestinal (GI) events 
(eg, diarrhea, nausea, upper abdominal pain, abdominal 
pain, and vomiting), proteinuria, and pruritus.28,29 Flushing 
and GI events are usually highest in the first few weeks 
of treatment and decrease thereafter.71 Flushing is a 
prostaglandin-mediated phenomenon that may be mitigated 
by pretreatment with aspirin,96 but the appropriate dose and 
schedule of administration of aspirin is not yet established 
for this purpose. While the exact mechanisms leading to 
GI events are not well known, the observation of transient 
eosinophilia in the gastric mucosa of patients treated with 
DMF suggested that the leukotriene-receptor antagonist 
montelukast may help to control some GI symptoms.97 
Moreover, it has been observed that consuming a high-fat 
and -protein meal soon before DMF administration may 
reduce GI and flushing side effects by effectively delaying 
intestinal absorption.98 In the daily clinical setting, dose titra-
tion with DMF 120 mg BID for 7 days, and then increased 
to 240 mg BID, is recommended to reduce the incidence of 
flushing and GI events. In some patients, a slower increase 
may be tried to enhance tolerability, based on weekly 
increases by 120 mg, as follows: first week, 120 mg OD; 
second week, 120 mg BID; third week, 120 mg and 240 mg 
daily; fourth week, 240 mg BID.99
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According to Phase III trials, the incidences of flushing 
and GI events range from 28% to 35% and 10% to 17%, 
respectively, and are of mild or moderate severity.28,29 
Although overall, the incidence of adverse events leading 
to treatment discontinuation was similar across the study 
groups (DEFINE, 13% in the placebo group and 16% in each 
of the DMF groups; CONFIRM, 10% in the placebo group, 
12% in each of the DMF groups, and 10% in the GA group), 
discontinuations due to flushing and GI events occurred 
more frequently in patients who received DMF than in those 
randomized to placebo. Discontinuations due to flushing and 
GI events were 2%–4% and 2%–6%, respectively, in patients 
treated with DMF versus #1% in placebo group.28,29
According to Phase III RCTs, at 1 year, white-cell and 
lymphocyte counts decrease by approximately 10%–12% 
and 28%–32%, respectively, in respect to baseline values. 
The incidences of grade 2 leukopenia (,3×109/L) and grade 
3 lymphopenia (,0.5×109/L) were 4%–10% and 4%–7% in 
the DMF groups, respectively, versus #1% in the placebo 
groups.28,29 A 35% reduction in ALC has also been reported 
after 3–6 months of DMF treatment in a real-world retro-
spective study. In this latter, grade 3 (ALC ,0.8×109) and 
grade 2 lymphopenia occurred in 24% and 5% of treated 
patients, respectively.83
A higher risk of lymphopenia has been noted in adults 
older than 55 years, in those with lower baseline lympho-
cyte counts, and in those switching from natalizumab.100 
Although incidences of infections and serious infections 
in RCTs are similar for patients on DMF and placebo, a 
theoretical increased risk for developing opportunistic John 
Cunningham virus (JCV)-mediated progressive multifocal 
leukoencephalopathy (PML) has been postulated in DMF-
treated patients with MS.
To the best of our knowledge, six cases of PML have been 
reported so far in patients receiving FAEs for psoriasis.101–107 
Notably, each of these patients had well-known risk factors 
for PML, including lymphocytopenia, sarcoidosis, cancer 
history, and prior efalizumab use.
One recent article assumes that there is no increased 
incidence of PML in DMF-treated patients with MS, and 
provides a mathematical model to estimate the risk of PML 
under immunotherapy assuming a constant incidence rate of 
three cases per million person-years.108 However, at the time 
of that publication, only one case of PML had been reported. 
To date, four cases of PML (one fatal) have occurred in DMF-
treated patients with MS who had not been treated before with 
other DMTs known to be associated with an increased PML 
risk. All cases occurred in subjects older than 50 years. Three 
of four patients had prolonged grade 3 lymphopenia prior 
to PML development. The remaining case had prolonged 
ALC 0.6×109 (corresponding to a grade 2 lymphopenia) for 
6 months before PML diagnosis.109
According to the European Medicines Agency, a base-
line brain MRI should be available as a reference, and a 
complete blood count is recommended prior to initiation of 
DMF and should be repeated every 3 months during treat-
ment for safety monitoring. Grade 3 lymphopenia should be 
monitored at even shorter intervals. Many clinicians advocate 
dosage reduction with grade 3 lymphopenia. DMF should be 
discontinued in cases of persistent grade 3 lymphopenia for 
6 or more months, and ALC monitoring should be provided 
until lymphopenia resolution. Where PML is suspected, 
treatment should be withdrawn immediately and appropriate 
diagnostic workup performed.109 Increased liver enzymes 
were transiently observed in the first few months of treatment, 
and in any case were accompanied by concurrent increase of 
bilirubin levels. DMF is not recommended for use in pregnant 
women (pregnancy category C).110
Selection of appropriate drug for 
individual patients
Before starting any DMT, neurologists must consider the 
patient’s views, requirements, and potential adherence 
difficulties. Treatment history (if applicable), psychological 
aspects potentially affecting treatment adherence, pregnancy 
desire, and coping strategies (especially in the newly diag-
nosed) should be carefully evaluated. The oral administration 
route of DMF is an attractive opportunity for patients, and 
may potentially provide an enhanced therapeutic adherence 
compared with self-injectable DMTs.58
Despite the efficacy of DMF 240 mg BID and TID being 
broadly comparable, DMF is authorized at 240 mg BID as 
first-line therapy for patients with an established diagnosis 
of R-MS. This “place in therapy” should allow neurologists 
to prescribe early over the course of the disease, before 
irreparable damage has occurred and when the chance to 
obtain a good therapeutic response is highest. This latter 
notion is supported by post hoc analyses combining data from 
DEFINE and CONFIRM showing that early treatment with 
DMF (defined as within 1 year from MS diagnosis or EDSS 
score #2) resulted in a stronger effect when compared to the 
whole intention-to-treat combined cohort.111,112 Consistently, 
subgroup analyses of the two pivotal RCTs showed that the 
treatment effect of DMF seems to be particularly great in 
patients who were treatment-naïve and in those with a lower 
baseline EDSS.113,114 However, DMF may be still effective 
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in patients with suboptimal response to prior treatment with 
IFNβ, as suggested by another integrated analysis of DEFINE 
and CONFIRM.90
The possibility of using DMF as an add-on treatment in 
patients who do not adequately respond to IFNβ or GA was 
investigated in the Phase II open-label EXPLORE study.115 
In this study, 108 patients with R-MS who experienced 
disease activity (defined as either one or more relapses 
within 12 months or on or more CELs on brain MRI within 
6 weeks prior to study enrollment) while under established 
treatment with IFNβ or GA for at least 1 year were submit-
ted to receive a 6-month course of DMF 240 mg TID in 
addition to their prescribed self-injectable DMT. Although 
the study was designed to test the safety and tolerability of 
add-on therapy, MRI activity was also investigated. Though 
DMF was used at a higher dosage (720 mg daily), the safety 
profile of its combination with IFNβ or GA was consistent 
with the known safety profile of DMF monotherapy. The 
exploratory MRI analysis showed a decrease in mean 
number of CELs and new T
2
-hyperintense lesions. Despite 
these promising results on the control of MRI activity, the 
EXPLORE study suffers from several weaknesses, includ-
ing a very short follow-up and lack of randomization and a 
control group.115 Therefore, future efforts should investigate 
the efficacy and longer-term safety profile of combining 
DMF with injectable DMTs in cases of suboptimal response 
to GA or IFNβ.
Use in JCV-positive patients
The possibility of using DMF as an effective exit strategy 
from natalizumab is under investigation.116 Other than 
natalizumab exposure, previous immunosuppression and 
to a greater extent seropositivity to JCV are the main risk 
factors for developing PML.116 As a result, the majority of 
patients at high risk of PML are advised to stop treatment.118 
Natalizumab discontinuation may induce the clinical and 
radiological disease reactivation that in some cases may lead 
to the accumulation of fixed disability.119 Currently, there 
are no evidence-based data or established guidelines driving 
specific treatment switching to control following natalizumab 
disease reactivation.
A recently published case report suggests that DMF 
may not be able to halt clinical and radiological following 
natalizumab disease reactivation in patients with highly 
active MS.120 However, preliminary results on 530 patients 
suggested that initiation of DMF within 90 days of washout 
after natalizumab withdrawal may represent a valid treat-
ment option with only minor safety concerns.115 In fact, 
the increased risk for PML in natalizumab is explained by 
the specific mode of action of this drug, which decreases 
immunosurveillance of the brain through its effect on the 
adhesion molecule located at the BBB level. By contrast, 
the mechanism of action of DMF does not seem to explain 
an increased risk for PML, unless severe lymphocyte deple-
tion occurs.100 Another proposed mechanism by which DMF 
may potentially induce PML encompasses its capacity to 
reduce binding of peripheral blood mononuclear cells to 
vascular cell-adhesion molecules.121 Potentially, this may not 
only preclude effective neuroimmunosurveillance for JCV 
infected cells but also may induce the release of premature 
B cells from marrow stores, which has been suggested to be 
implicated in viral expression and transformation.122
However, screening for anti-JCV antibody status is not 
recommended for DMF treatment. A possible diagnosis 
of preclinical PML should be ruled out in patients who 
discontinue natalizumab before starting DMF. In light of 
the increased risk of DMF-induced lymphopenia in patients 
previously treated with natalizumab,100 stringent monitoring 
of differential blood count and prompt DMF discontinuation 
in the event of a 6-month sustained grade 3 lymphopenia are 
recommended to reduce the risk of PML.109 Special attention 
should also be paid to older patients changing treatment from 
natalizumab to DMF.100
What if treatment fails?
As required for all other first-line DMTs, once the therapy 
is started, the response to DMF should be carefully assessed 
to identify patients early who experience breakthrough 
disease.47 If relapses and MRI activity occur in the first few 
months from DMF beginning, the possibility of a delayed 
treatment effect should be considered and therapy with 
DMF continued. This suggestion comes from findings from 
a Phase IIB RCT showing that the control of BBB was 
delayed up to 8–12 weeks from treatment start.85 In cases of 
disease activity 6–12 months after treatment start, a prompt 
switch to an alternative and more effective drug should be 
considered to avoid further relapses and the accumulation of 
fixed disability over time. In this scenario, we recommend 
not trying all available first-line DMTs, but an escalation to 
second-line DMTs, such as natalizumab and alemtuzumab, 
is warranted.53,55
Based on a recent systematic review with mixed-treatment 
comparisons, DMF seems to have no significant difference 
in terms of efficacy (ARR) when compared to fingolimod, 
and even to be superior to teriflunomide.123 However, several 
methodological concerns have been raised for carrying out 
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indirect comparisons of treatment arms across RCTs as done 
by Hutchinson et al,123 and thus further studies based on more 
advanced statistical approaches (eg, network meta-analysis) 
are warranted to better compare the efficacy and safety of 
different DMTs.124 In the absence of head-to-head compari-
son RCTs, the best way to indirectly assess the benefit of 
DMTs across different independent studies is absolute risk 
reduction, which is very similar for DMT, fingolimod, and 
teriflunomide, ranging from 17% to 22%.
Other aspects should also be taken into consideration. 
Despite its supposed inferiority in reducing the ARR, 
teriflunomide is the only oral agent that met the disability-
worsening end point in two independent trials.26,27 In addition, 
fingolimod is the only oral agent that demonstrated a signifi-
cant reduction in brain-volume loss compared to placebo,24 
while DMF and teriflunomide did not meet the brain-atrophy 
end point.26,89
With regard to tolerability, discontinuation due to side 
effects has been reported to be higher with DMF than 
fingolimod.125 Therefore, we might suggest switching from 
DMF to fingolimod (or teriflunomide) predominantly in cases 
of intolerable GI events or other side effects. However, teri-
flunomide may be associated with teratogenicity, thus con-
traindicating its use in potentially childbearing women.110
Conclusion
A treatment algorithm based on the efficacy and safety pro-
file of DMF is proposed in Figure 1. For newly-diagnosed 
patients with R-MS, we suggest considering first-line treat-
ment with DMF over self-injectable therapies, due to its 
demonstrated efficacy, simplicity of treatment initiation, and 
administration route. Phase III RCTs have demonstrated its 
success as an efficacious oral DMT with a favorable toler-
ability and safety profile.28,29 The early side effects of DMF, 
such as GI and flushing reactions, tend to decrease with time 
on therapy and are generally self-limited.71
Patients experiencing breakthrough disease with self-
injectable DMTs may be favorably switched to DMF,123 but 
in cases of relapse with residual disability might be recom-
mended to escalate to high-efficacy monoclonal antibodies 
(natalizumab, alemtuzumab). This latter suggestion also 
comes from subgroup analysis of RCTs showing that the 
treatment effect of oral drugs seems to be particularly great 
in patients with a lower EDSS.113,114 An escalation strat-
egy, rather than a switch to other oral drugs (fingolimod or 
teriflunomide), is even suggested in patients who have failed 
DMF treatment,123 while there are still no recommendations 
or suggestions to manage patients with subclinical disease 
activity while on DMF.
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Figure 1 Proposed treatment algorithm for treating R-MS with DMF.
Notes: aConsider pregnancy desire; bconsider anti-vZv serological status, comorbidities, and concomitant non-MS treatments (eg, cardiac illnesses, antihypertensive drugs); 
cconsider anti-JCv serological status; dconsider anti-vZv serological status, latent tuberculosis, and HPv screening. Please note that this algorithm, though based on currently 
available literature data, represents the authors’ opinion only.
Abbreviations: R-MS, relapsing multiple sclerosis; DMF, dimethyl fumarate; vZv, varicella zoster virus; JCv, John Cunningham virus; HPv, human papillomavirus; DMTs, 
disease-modifying treatments.
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Based on its putative antioxidative cytoprotective effect, 
DMF may also be considered as a therapeutic option for pro-
gressive forms of MS.126 However, a Phase III RCT aimed at 
investigating whether DMF (compared with placebo) slows 
disability progression not related to relapses in secondary 
progressive MS has recently been terminated by sponsor 
decision.127
In conclusion, DMF is a promising candidate for newly 
diagnosed treatment-naïve patients with R-MS, and a possible 
switching option in some selected cases (especially in cases 
of poor tolerability or safety concerns with other DMTs).
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